Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy

NCT07354932 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07354932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07354932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
March 9, 2026
Completion date
December 31, 2027
Enrollment
84 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy